Kraig Biocraft Laboratories In Stock Price, News & Analysis

Kraig Biocraft Laboratories (OTCQB: KBLB) has secured a new investment license in Vietnam, marking a significant milestone in its expansion strategy. This authorization enables the company to scale up its production operations to meet growing demand for its spider silk-based fibers.

The expansion will enhance Kraig Labs' capacity to supply its innovative materials to various markets, including textiles, defense, and medical sectors. The company plans to develop advanced rearing facilities in Vietnam, focusing on environmentally sustainable practices while producing strong, lightweight, and eco-friendly materials.

CEO Kim Thompson emphasized that this license demonstrates confidence in their technology and positions them to expand their production footprint, making cost-effective spider silk production a reality.

Kraig Biocraft Laboratories (OTCQB: KBLB) has secured a $10 million standby equity purchase agreement (SEPA) with YA II PN, (Yorkville) to support its spider silk production expansion and commercialization efforts. The agreement provides flexible access to capital over the next 36 months, with no minimum use requirements or operational restrictions.

The SEPA is designed to help bridge the company's transition to revenue generation, allowing Kraig Labs to strategically access funds for building production capacity, developing spider silk inventory, creating new consumer products, and establishing sales partnerships. The company maintains full discretion over if and when to utilize this funding.

Kraig Biocraft Laboratories (OTCQB: KBLB) has announced a breakthrough in spider silk technology with the successful creation of a new transgenic inspired by the Darwin's bark spider. The company has integrated key genetic sequences from the Darwin's bark spider, known for producing the toughest biological material ever measured (10 times tougher than para-aramid fibers used in bulletproof vests), into their proprietary silkworms.

This development combines the exceptional properties of Darwin's bark spider silk with traditional silkworm silk production efficiency, targeting applications in textile, defense, medical, and industrial sectors. The company's COO, Jon Rice, indicated that this breakthrough is one of many recent achievements, with expectations for continued developments in 2025 alongside metric ton production of existing hybrids.

Kraig Biocraft Laboratories (OTCQB: KBLB) reports significant achievements in 2024 with its BAM-1 hybrids, the world's first commercially viable silkworms for recombinant spider silk production. The breakthrough technology has demonstrated remarkable results, including doubled cocoon size compared to traditional silkworms and enhanced silk yields. The company produced over 1,200 pounds of recombinant spider silk cocoons this year.

The BAM-1 hybrids' exceptional robustness and resilience have advanced scalability and consistency for large-scale commercial operations. Applications include technical textiles, defense, medical devices, and performance apparel. The company plans to expand production to multiple tons of spider silk in 2025.

Kraig Biocraft Laboratories (OTCQB: KBLB) has achieved a significant production milestone, manufacturing over 1,200 pounds of recombinant spider silk cocoon in the past 12 months. This output exceeds the combined production of all previous years, marking a major breakthrough in commercialization efforts.

The record-setting production was achieved through the company's newest hybrid spider silk production strain, which modified traditional silkworms to produce spider silk-based fibers. This advancement demonstrates Kraig Labs' success in scaling up from laboratory innovation to sustainable commercial production, positioning the company to address global demand for performance fibers across various consumer markets.

Kraig Biocraft Laboratories (OTCQB: KBLB) announced an investor web conference scheduled for December 4, 2024, at 4:30 pm ET. The conference will showcase the company's achievements in commercializing spider silk fibers over the past year. CEO Kim Thompson highlighted record-setting progress in scaling up spider silk production and developing next-generation super fibers. The presentation will be available on the company's website and YouTube channel, covering business model progress and upcoming targets.

Kraig Biocraft Laboratories (OTCQB: KBLB) has successfully completed its fourth production cycle for 2024, achieving record-setting performance in parental silkworm lines and hybrid cocoons. The latest batch set new records for cocoon size, shell weight, and other key metrics for large-scale production of their BAM-1 spider silk line. The company reports improvements in both hybrid cocoons and parental silkworm lines, demonstrating comprehensive advancements throughout the production process. These achievements strengthen their position in sustainable, high-performance fiber production and indicate readiness for scaling to multi-ton production levels.

Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB), the leading developer of spider silk-based fibers, has announced plans to host an investor web conference in the coming weeks. The conference will provide an in-depth review of the Company's progress over the past twelve months in commercializing its revolutionary spider silk technology.

The upcoming conference will cover recent advancements, detailed production metrics, and critical developments accelerating Kraig Labs' trajectory to bring its spider silk technology to market. Attendees can expect insights into total spider silk production, development of next-generation spider silk fibers, targeted markets for early adoption, and projections for production levels in 2024.

Company Founder and CEO, Kim Thompson, expressed excitement about sharing the substantial progress made in scaling up spider silk production. The Company is finalizing event details, with a follow-up announcement to be made as the event approaches.

Kraig Biocraft Laboratories (OTCQB: KBLB) announces the near completion of its largest production batch of BAM-1 parental line spider silk silkworms. This milestone marks the achievement of true commercial-scale levels of parental strain production. The current batch is cocooning this week, with the production team reporting strong growth and great colony health.

CEO Kim Thompson states this production cycle will deliver the largest supply of BAM-1 production hybrid eggs in the company's history. This success verifies the scalability of Kraig Labs' spider silk technology, positioning the company to deliver commercial quantities to partners and customers. The results will supply Kraig Labs with millions of BAM-1 production hybrids for commercial production, marking a transition from development to a true production focus.